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nificantly associated with any outcome. Finally, we found thatOutcome of relapse in lupus nephritis: Roles of reversal of
failure of disease to remit also is associated with a high raterenal fibrosis and response of inflammation to therapy.
of CRX2 (64.8% vs. 13.0%, P  0.00034).Background. Renal relapse in lupus nephritis has been
Conclusions. Interstitial fibrosis and glomerular scarring inshown to have ominous prognostic significance with the major-
systemic lupus erythematosus are partially reversible, and thisity of patients progressing to doubling of serum creatinine
reversal is attended by an excellent outcome. The outcome of(CRX2). However, not all patients do so. This report explores
renal relapse is determined by the initial response of inflamma-the roles of response of inflammation to therapy and of glomer-
tory and chronicity elements to therapy, those with prior partialular scarring and interstitial fibrosis and their potential reversal
reversal of interstitial and glomerular scarring having a goodto outcome of renal relapse.
outcome, and those in whom fibrotic lesions have continuedMethods. Renal biopsies from 71 patients with lupus nephri-
tis with an initial biopsy (Bx1) and systematic control biopsy to increase and have a poor outcome. Inflammatory variables
(Bx2) after six months of therapy, as well as subsequent biop- appear to be more important in determining outcome than
sies for clinical indications, were studied. The relationships of immunoglobulin deposits.
morphologic factors to renal relapse and its outcome as well
as to CRX2 and end-stage renal disease (ESRD) were ana-
lyzed. Cox proportional hazards modeling was used to assess
In studies reporting on 71 patients with initial andassociation of morphologic variables with outcomes.
systematic six-month biopsies after induction treatment,Results. Renal interstitial fibrosis and glomerular segmental
scarring were partially reversible in 17 and 11 patients, respec- we found that the initial biopsy had very little predictive
tively. This decline was associated with an excellent prognosis, ability [1, 2]. However, at the six-month biopsy a number
with only one patient in each group (5.9% and 9.1% respec- of morphologic variables were predictive of progressiontively) progressing to CRX2. All 18 patients who progressed
to doubling of the serum creatinine (CRX2) and end-to CRX2 either failed to respond to therapy (7 patients) as
stage renal disease (ESRD). In ascending order of pre-defined by normalization of serum creatinine (SCr) and reduc-
tion of proteinuria to1 g/day, or relapsed after initial response dictive strength, these included persistent subendothelial
(11 patients), as defined by recent rise of SCr 50% and/or and mesangial deposits (as reported by others as well
proteinuria3.5 g/day. However, relapse also occurred in 11 of [3]), overall immune deposits (particularly C3) by immu-47 other patients without progression to CRX2. These patients
nofluorescence (IF), and most importantly, the ongoingshowed a greater initial response of inflammation and deposits
presence of inflammatory elements, such as cellular cres-to therapy and fibrous lesions partially reversed in the period
prior to relapse, so that active lesions were superimposed on cents and macrophages in the tubular lumens. However,
a lower level of chronic lesions. By contrast, chronic lesions a bothersome question is why the results of a biopsy at
mounted steadily in those who progressed to CRX2. Cox pro-
six months can be predictive of events that might occurportional hazards modeling indicated a strong association of
as much as five to ten years in the future, with numerousinflammatory variables with renal relapse, CRX2 and ESRD.
However, the extent of immunoglobulin deposits was not sig- clinical events intervening in the meantime, particularly
renal relapse [4, 5] or the failure to go into remission
[6], both of which have been shown to be major risk
1Current location, the Hoˆpital Foch, Suresnes, France. factors for progression. This study investigates the fac-
tors that determine whether or not a patient with a renalKey words: renal relapse, interstitial fibrosis, glomerular scarring, sys-
temic lupus erythematosus, progressive renal disease. relapse will progress to CRX2.
An allied issue was the role of fibrotic lesions in pro-Received for publication June 21, 2001
gression. Intuitively, one would anticipate that the leveland in revised form December 7, 2001
Accepted for publication January 14, 2002 of chronic lesions would be predictive of outcome, and
a number of groups indeed have found this to be the case 2002 by the International Society of Nephrology
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[7–16]. In our studies, though, they were not predictive at tos were reviewed separately in random order by the
same pathologist.either Bx1 or Bx2. Further study reveals they do play a
Standard clinical parameters were evaluated at therole, but not in the manner anticipated.
time of each biopsy as previously reported [1, 2]. Clinical
data were available for all patients for the initial two
METHODS biopsies; however, the follow-up data as to outcome were
Patient population incomplete for six patients (2 focal, 3 diffuse, and 1 mixed
membranous and proliferative).Renal biopsies and clinical data from 71 patients from
The following definitions were used regarding treat-four Paris hospitals (Bichat, St. Louis, Broussais, and
ment and response.Henri Mondor) from the period 1986 to 1994 were evalu-
Therapeutic response. Defined as reduction of pro-ated. The patients were involved in a protocol for treat-
teinuria to 1 g/day and normalization of serum creati-ment of lupus nephritis, the majority (55 patients) with
nine (SCr). Hematuria, not included in the definition, alsoWHO Class IV lesions on initial biopsy, but also nine
was reduced to 10,000 red blood cells (rbc)/mL in allpatients with relatively extensive Class III lesions and
but two patients, one who went on to CRX2 and one whoseven patients with mixed membranous and proliferative
did not, although this reduction in hematuria frequently(Class Vc and Vd) lesions according to the 1982 WHO
took more time than the reduction in proteinuria.criteria [17]. Cases were accepted as diffuse proliferative
Renal relapse. Relapse was defined as recrudescencelupus nephritis with as few as five glomeruli provided
of renal disease after an initial therapeutic responseall five showed proliferative lesions. No case of focal
shown by a recent increase of SCr by 50% with activeproliferative GN or of mixed membranous and focal
urinary sediment (nephritic relapse) or increase in pro-proliferative GN was diagnosed with fewer than ten glo-
teinuria to 3.5 g/day or greater (nephrotic relapse). Casesmeruli. The mean number of glomeruli/biopsy did not
with nephritic relapse frequently had elevations, some-differ significantly between the three biopsies, ranging
times marked, in proteinuria as well [4].between 16.5  9.9 to 20.4  12.0. On Bx2 and Bx3, the
Renal remission. A reduction of proteinuria to 0.33minimum number of glomeruli for each biopsy was four,
g/day and SCr to 123 mol/L at any point in the coursewith 164 of 174 (94.3%) biopsies in the study having
defined remission.seven or more glomeruli. Criteria for acceptance of cases
Three outcome parameters were evaluated in this study:into the study and demographic distribution are given
(1) Doubling of the initial serum creatinine (CRX2) for
in a prior communication [1].
three months or more, the outcome measure used in a
All patients had an initial renal biopsy (Bx1), followed number of recent studies in lupus nephritis [4, 5, 7–9,
by six-month induction treatment consisting of monthly 18–20]; (2) ESRD requiring dialysis and/or transplant;
intravenous cyclophosphamide [0.7 g/m2 body surface (3) final renal function (RFlast), with the last SCr measure-area (BSA)] combined with prednisone (0.9 0.4 mg/kg ment having an arbitrary value of 500 mol/L assigned
body weight/day for one month tapered to 0.4  0.1 to all patients with ESRD, whether they were on dialysis
mg/kg body weight/day at 6 months) in 58 patients, and or transplanted.
corticosteroids alone in 13 patients (1.4 0.3 mg/kg body
weight/day tapered to 0.5 0.16 mg/kg body weight/day Morphologic variables
at 6 months). Initial treatment was followed at six months The schema for evaluation of morphologic variables
by control renal biopsy (Bx2) to evaluate the effects of has been reported in detail in our earlier studies [1, 2].
therapy. Subsequent biopsies were performed primarily Briefly, the method of grading morphologic lesions paral-
for clinical indications, with some patients having as lels that used by Austin et al, using the same grading
many as five biopsies total. Follow-up varied from 4.5 system of 0 to 3, but adding consideration of tubular
years to 12.5 years, with an average of 7.0 years. lesions and IF data [7]. The definitions of Austin et al
were strictly applied for the standard variables [7] with
Technical methods and record review the exception of glomerulosclerosis, which was divided
Specifics of the technical methods are given in a prior into totally sclerotic glomeruli and glomeruli with seg-
communication [1]. Briefly, light microscopic slides were mental scars, with each being recorded separately. In
prepared and stained according to standard methods for the Biopsy Index, glomerular and tubular macrophages
light and IF microscopy. All IF material reported in this were estimated semiquantitatively from routine stains,
study was processed at the Hoˆpital Broussais, all positive and subsequent studies have shown these semiquantita-
antisera were reviewed with systematic photography, tive estimates to have an excellent correlation with mac-
and the data reported by the same personnel. All biopsies rophages stained for CD68 (PGM1) and counted mor-
were evaluated in random order by a pathologist (GSH) phometrically [2].
An Immunofluorescence Index (IFI) was devised inwho was blind to the clinical data. Similarly, the IF pho-
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Table 1. Components of the Biopsy Indexthe following manner. Antisera to the following were
employed in all cases: IgG, IgA, IgM, C3, C1q, and fi- Abbreviation Scale
brinogen. Four separate morphologic IF components Glomerular Activity
were evaluated: glomerular capillary, glomerular mesan- Index (GAI)
Glomerular proliferation glprolif 0–3gial, vascular, and tubulointerstitial. Staining for each anti-
Polymorphonuclearserum was graded on a scale of 0 to 4 for each compo- leukocytes glpmn 0–3
nent, relying primarily on extent rather than brightness. Karyorrhexis/Fibrinoid
necrosis karyfib (0–3) X2The totals for all the antisera were then added for a
Cellular crescents cresc (0–3) X2maximum of 24 for each component. In addition to the Hyaline deposits hyaldep 0–3
IFI, total staining for each antiserum was calculated, Glomerular monocytes glmono 0–3
Maximum: 24for a maximum of 16/antiserum. In addition, glomerular
Tubulointerstitial Activitycapillary deposits were divided by location, subendothel-
Index (TIAI)
ial versus subepithelial, on photographs of the IF, as Tubular cell pyknosis tubpyk 0–3
Tubular nucleardescribed previously [2].
‘activation’ tubact 0–3Arterial and arteriolar light microscopic lesions are not
Tubular cell necrosis tubnec 0–3
included in this study because their correlations with clini- Tubular cell flattening tubflat 0–3
cal and outcome variables are relatively weak [1]. In this Macrophages in tubular
lumens macrlum 0–3study only vascular IF was included. The Biopsy Index and
Epithelial cells in tubularits abbreviations are delineated in Table 1. In addition, the lumens eplum 0–3
composite variables of total immunoglobulin deposits Interstitial inflammation intinfl 0–3
Maximum: 2(Total Ig  IgG  IgA  IgM) and biopsy inflammation
Chronicity Lesions Index(BxInflkary/fib cresc glmonos tubmacr intinfl) (CI)
are used extensively throughout this article. Glomerulosclerosis glscl 0–3
Glomerular scars gloscar 0–3
Fibrous crescents fibcres 0–3Statistical analyses
Tubular atrophy tubatro 0–3
For correlations between variables, Pearson product- Interstitial fibrosis intfib 0–3
Maximum: 15moment correlation coefficients or Spearman rank order
Immunofluorescence Indexcorrelations were used as appropriate, as previously de-
(IFI)
scribed [1, 2]. The influence of multiple morphologic Glomerular capillary IF glcapif (0–4) X6 antisera
Glomerular mesangial IF glmesif (0–4) X6 antiseravariables on the risk of renal relapse, CRX2 and ESRD
Tubulointerstitial IF tubulif (0–4) X6 antiserawas assessed using the Cox proportional hazards regres-
Vascular IF vascif (0–4) X6 antiserasion model, using only cases with complete light micro- Maximum: 96
scopic, IF, and follow-up data. Comparisons of survival












in survival curves evaluated by log rank sum testing.
The Biopsy Index is comprised of each of the individual indices, normalized
to 3 maximum by division by appropriate number of components.
Biopsy Inflammation (BxInfl)  glpmn  karyfib  cresc  glmono  tub-RESULTS
macr  intinfl
Total Immunoglobulin (Total Ig)  IgG  IgA IgMChanges in the Chronic Lesions Index (CLI) and its
variables during therapy
Cases were divided into those who doubled their SCr
(CRX2) levels and those who did not (No CRX2). As proteinuria, whereas the Intfib↓ group had largely cleared
anticipated, overall the CLI and its component variables their proteinuria. Importantly, tubular epithelial lesions
progressively increased in severity (Fig. 1). However, in decreased in the Intfib↓ patients, but remained high in the
a number of cases these variables decreased rather than
Intfib↑ group. Furthermore, other morphologic variablesincreasing from one biopsy to the next. These cases were
tended to move in parallel with interstitial fibrosis. Thelargely confined to the No CRX2 group, where in three
Intfib↓ group had an excellent outcome, with only oneinstances there was a steady decrease over three succes-
patient (5.0%) going on to CRX2. By contrast, the Intfib↑sive biopsies (from Bx1 to Bx3 in 2 instances and from
group had a parallel increase in other parameters, andBx2 to Bx4 in the third).
had a high rate of CRX2 and ESRD. Sampling error asInterstitial fibrosis. Table 2 compares 17 patients in
an explanation for the overall differences was ruled outwhom there was a decrease in interstitial fibrosis (Intfib↓)
by 2 testing for distribution between groups of CRX2with 28 patients whose fibrosis increased (Intfib↑) from
(P  0.00002) and ESRD (P  0.00001).Bx1 to Bx3 (or Bx2 for cases with no third biopsy). Al-
Glomerular scars. Similarly, in 11 patients there wasthough proteinuria was roughly equal in the two groups
at Bx1, at Bx2 those who progressed still had substantial a reduction in segmental glomerular scarring (Gloscar↓)
Hill et al: Relapse in lupus nephritis 2179
Fig. 1. Chronic Lesions Index in the (A) no serum creatinine doubling (No CRX2; N  47 patients) and (B) serum creatinine doubling (CRX2;
N  18 patients) groups. Note that a number of cases diminish the severity of chronic lesions in the No CRX2 group, whereas they mount
progressively in the CRX2 group.
between Bx1 and Bx3 (or Bx2 for cases with no Bx3).
Comparison with 30 patients in whom glomerular scarsTable 2. Comparison of cases with decrease versus
increased (Gloscar↑) revealed that although there wereincrease of interstitial fibrosis
no significant differences in either proteinuria or SCr atInterstitial fibrosis
any of the three biopsies, the outcome was much more
Decreases Increases favorable in the Gloscar↓ group, with a lower rate of(17 patients) (28 patients) P
CRX2 (9.1 vs. 40.0%, P 0.06) and lower final SCr value
Proteinuria–Bx1 4.33.5 5.43.4 NS (119  134 vs. 248  190, P  0.04).Proteinuria–Bx2 0.70.8 2.02.7 0.03
This diminution of glomerular scarring appears to beProteinuria–Bx3 1.42.2 3.42.6 0.07
SCr–Bx1 9533 12743 0.01 real. First, sampling error was once again ruled out by
SCr–Bx2 8314 11262 0.08 2 testing for CRX2 (P 0.000000). Secondly, interstitialSCr–Bx3 8616 13264 0.08
fibrosis was significantly lower at Bx3 in the Gloscar↓ESRD 0.00% 28.6% 0.02
CRX2 5.9% 35.7% 0.03 group (0.87  0.69 vs. 1.69  0.90, P  0.0415). Finally,
RFlast 11589 231187 0.02 global glomerulosclerosis also was lower in the Gloscar↓
Interstitial fibrosis 1 0.970.56 0.440.54 0.004 group (0.75  1.16 vs. 1.08  0.86, NS), arguing against
Interstitial fibrosis 2 0.630.54 1.260.68 0.002
progression of scars to global glomerulosclerosis as theInterstitial fibrosis 3a 0.620.44 1.680.93c 0.007
Interstitial inflammation 1 1.310.60 1.271.03 NS explanation for the decline. As with Intfib↓ patients, tu-
Interstitial inflammation 2 0.420.55 0.800.64 0.05 bular epithelial lesions and biopsy inflammation are sig-
Interstitial inflammation 3a 0.310.37c 1.461.17 0.01
nificantly lower in the Gloscar↓ group.
Tubular epithelial 1b 3.651.89 4.572.76 NS
Tubular epithelial 2 2.031.70 4.742.38 0.0002 Role of response to therapy and renal relapse
Tubular epithelial 3a 1.751.28c 4.713.12 0.02
in progression
Chronic Lesions Index 1 2.722.11 2.021.99 NS
Not surprisingly, failure to respond to therapy (definedChronic Lesions Index 2 2.352.08 4.672.56 0.003
Chronic Lesions Index 3a 2.371.62 5.532.95c 0.006 as proteinuria 1 g/day and normalization of SCr) was
attended with a disastrous outcome. Seven of nine pa-Biopsy inflammation 1 4.592.17 6.593.59 0.05
Biopsy inflammation 2 1.121.49 2.222.17 0.07 tients who failed to respond went on to CRX2. The
Biopsy inflammation 3a 0.561.01c 3.252.69c 0.01 remaining two patients died in renal insufficiency (SCr 
The Table includes only patients with a complete follow-up. Decreases and 325 and 360 mol/L, respectively) but did not technicallyincreases are defined in terms of decrease/increase in interstitial fibrosis between
Bx1 and Bx3, or between Bx1 and Bx2 if there is no third biopsy. Twenty patients double their SCr value for the requisite three months.
had no net change in interstitial fibrosis between biopsies. For those who responded initially, renal relapse wasa At Bx3 there were only 8 biopsies in the decrease group and 14 biopsies in
the increase group a major risk factor for progression to CRX2 (Fig. 2). Of
b Tubular epithelial  tubpyk  tubact  tubnec  tubflat  eplum the 56 patients who responded to therapy, all of thosec Differences between Bx1 and Bx3 significantly different (P  0.05) for that
group who progressed to CRX2 (11 patients) had subsequent
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instances the declines were much greater for BxInfl than
for IF variables at BX2. (4) At the time of renal relapse
at Bx3 there was a recrudescence of IF variables and
BxInfl in both the CRX2 and Relapse-No CRX2 groups.
In contrast, these parameters continued to decline in
the No Relapse-No CRX2 group. (5) Data at Bx4 were
limited, and there were only five biopsies in the CRX2
group and three in the No Relapse-No CRX2 group, but
they suggest that once again deposits and inflammation
were reduced more in the No Relapse-No CRX2 group
than in the CRX2 group (Fig. 4).
Some specific comments should be added regarding
the contrasting behaviors of Total Ig and C3 (Fig. 3A).
Behavior of Ig deposits did not differ greatly between the
three groups. However, C3 in the CRX2 group differed
substantially; it started at Bx1 at significantly higher lev-
Fig. 2. Ten-year survival rate from CRX2 showing therapeutic re- els and declined by much less at Bx2. Finally, relapse
sponse and renal relapse. Symbols are: (solid line) Response-No Re-
was marked in both groups by much greater relativelapse; (dotted line) Response-Relapse; (dashed line) No Response; ()
complete; () censored. The percentages are: Response-No Relapse, changes in C3 than Ig deposits.
100%; Response-Relapse, 42.7%; No Response, 12.7%. Survivals are Examination of the Chronic Lesions Index (CLI; Fig.
calculated from time 0, but curves begin at first event, completion or
3C) at the three biopsies gives some insight into why—censoring. Asterisks indicate patient deaths and are confined to the No
Response group. Both patients in this group who did not technically despite similar levels of active lesions at Bx3—the CRX2
qualify as doubling their SCr for 3 months or more, nonetheless died in group progressed to renal insufficiency whereas the Re-
marked renal insufficiency (SCr  325 and 360 mol/L, respectively). lapse-No CRX2 group did not. In the CRX2 group the
CLI continued to mount between Bx2 and Bx3, whereas
in both of the No CRX2 groups it actually declined.renal relapses versus 11 relapsing patients among the 45
patients who did not progress to CRX2 (P  0.0058). Role of remission in progression
Nephritic relapses were more frequent and had a worse
The influence of remission, defined by Korbet et al asprognosis than those with proteinuric relapses: 10 of 16
SCr123mol/L and proteinuria less than 0.33 g/24 h [6],nephritic relapses versus 1 of 8 patients with proteinuric
was examined on outcome. We found that remission wasrelapses went on to CRX2 (P  0.02).
associated with an 87.0% 10 year survival from CRX2
We compared the CRX2 group with the No CRX2
versus 35.1% for those who did not remit (P  0.00034).
group, which was subdivided into those who did relapse
(Relapse-No CRX2) and those who did not (No Relapse- Morphologic factors associated with renal relapse and
No CRX2). We compared data at the first, second and progression to CRX2 and ESRD
third biopsies (excluding 2 patients whose 3rd biopsies At the time of the initial biopsy, the sole morphologic
were not contemporaneous with their relapse). Differ- variables predictive of future behavior were vascif and
ences in clinical values among the groups were modest. C3 [1, 2]. Univariate analysis at Bx2 revealed a number
The Relapse-No CRX2 group showed lower CH50, and of variables associated with subsequent relapse and pro-
greater hematuria and proteinuria at Bx1 and greater gression (Table 3). Cox proportional hazards modeling
hematuria at Bx2 than the No Relapse-No CRX2 group. was performed to ascertain the association of these vari-
At Bx3, the No Relapse-No CRX2 group had less pro- ables with renal relapse, CRX2 and ESRD (Table 4).
teinuria than the two groups with relapse. To have a global impression for the relative significance
The morphologic differences are easiest appreciated of immunoglobulin deposits, inflammatory lesions, and
graphically. Figure 3A shows the relative values for Total chronic lesions, the composite variables of Total Ig,
Ig and C3 deposits, and Figure 3B those for BxInfl. For BxInfl, and CLI were used. Prior survival analyses had
easier comparison, values are indexed such that the val- revealed that each of the composite variables was a
ues at Bx1 for the No Relapse-No CRX2 group  1. stronger predictor than any of its individual components
Several points should be made: (1) Values for patients or any lesser combination of them [2].
destined to CRX2 started at slightly higher means at BxInfl was highly associated with all three outcomes
Bx1, but only the differences in C3 were statistically with very respectable 	s, but Total Ig had weak 	s, none
significant. (2) At Bx2, the values for both sets of parame- of which was significant. Chronic lesions were not sig-
ters declined, but those for the No CRX2 groups declined nificantly associated with any outcome and only at Bx3
were they finally significantly associated with CRX2 (	much more dramatically than those for CRX2. (3) In all
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Fig. 3. Comparisons of CRX2, Renal Relapse–No CRX2, and No Relapse-No CRX2 groups. (A) Total immunoglobulins and C3. (B) Biopsy
inflammation. (C) Chronic Lesions Index. (D) Biopsy Index. Note that response to treatment at Bx2 is much greater for both Total Ig and C3
and BxInfl in the Relapse-No CRX2 and No Relapse-No CRX2 groups. Relapse at Bx3 shows increase of both C3 and BxInfl. In panel C, the
chronicity elements decline in the two No-CRX2 groups but continue to mount in the CRX2 group. The Biopsy Index, in effect a summation of
the active and chronic components, remains high throughout in the CRX2 group, but descends in the No CRX2 groups.
Fig. 5. Glomerulus with massive hyaline de-
posits and intracapillary coagula but minimal
inflammation. Intraglomerular proliferation
and inflammation are nearly absent, and there
is almost no surrounding interstitial inflam-
mation. Periodic acid-Schiff (PAS) stain;
350.
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mate concern is that these might be overlapping vari-
ables, all describing basically the same group of patients
with good prognosis. Morphologically this is not the case.
As might be expected, there was overlap between the
Intfib↓ and Gloscar↓ groups; four patients fell into both
groups out of 11 and 17 patients, respectively. However,
only three patients (5.6%) had both initial marked de-
posits and a decrease in interstitial fibrosis, compared to
4.6% who would be predicted statistically if these were
independent variables. Nor is this the case for the clinical
variable, lack of renal relapse. Compared to the overall
incidence of renal relapse (33.8%), the marked hyaline
deposits group had 35.7% relapses (NS), the Gloscar↓
group 37.3% (NS), and the Intfib↓ group 29.7% (NS).Fig. 4. Biopsy inflammation in the CRX2 and Renal Relapse-No CRX2
Groups. Symbols are: (dotted lines) CRX2; (solid lines) Renal Relapse-
No CRX2; (thick solid lines) group means. BxInfl responds to therapy
significantly better in the Renal Relapse-No CRX2 group at Bx2 and DISCUSSION
likely does so again at Bx 4, but data are too limited to be significant.
Diminution of interstitial fibrosis and(The No Relapse-No CRX2 group is excluded from consideration).
glomerular sclerosis
There is a tendency to think of glomerular and intersti-0.3363, P  0.01). In contrast with Total Ig, the 	s of
tial fibrosis as cumulative and immutable, despite theC3 deposits were significantly associated with all three
fact that it is known that the amount of extracellularoutcomes, increasing with worsening outcomes. Other
matrix (ECM) depends on the balance between its accu-individual associated variables were either inflammatory
mulation and its degradation. Degradation of ECM de-in nature, or in the instance of epithelial cells in tubular
pends on metalloproteinases (MMPs) and plasmin thatlumens, reflected ongoing tubular damage.
degrade collagen and other matrix components, and is
countered by tissue inhibitor of metalloproteineases-1Relative dissociation of glomerular hyaline deposits
(TIMP-1) and plasminogen activator inhibitor-1 (PAI-1),and inflammation
which block degradation as these inhibitors are associ-
As has been described by others [17] and noted by ated with an influx of macrophages [21–23]. In most in-
virtually everyone, we observed that there were a num- stances the balance between accumulation and degrada-
ber of cases at Bx1 of diffuse proliferative disease with tion is altered in favor of progressive fibrosis. However,
massive hyaline subendothelial and intracapillary depos- clear cut reversal of glomerular sclerosis and interstitial
its but with limited proliferative and inflammatory le- fibrosis has been demonstrated in several animal models
sions (Fig. 5). These cases, defined as those with 3 [24–28]. Specifically, as regards MMPs and their inhibi-
hyaline deposits and BxInfl 7.0 (mean value for cases tors, in one study of puromycin aminonucleoside (PAN)
with diffuse proliferative lesions) were compared with nephrosis [24], a single injection of PAN led to fibrosis
the remaining cases of diffuse proliferative lupus (Ta- early on that was accompanied by up-regulation of
ble 5). Clinically, they differed significantly only at the TIMP-1, although MMPs remained relatively constant,
last biopsy, Bx3. However, the outcome in the group followed by resolution of the fibrosis over several weeks
with massive deposits but little inflammation was much with diminution in TIMP-1 as fibrosis resolved.
better, with no ESRD (vs. 35.2% for the remaining cases, In our study a number of cases showed diminution of
P  0.013) and better final renal function (SCr  100  the extent of interstitial fibrosis and glomerular sclerosis
62 vs. 261  199 mol/L, P  0.0044). Morphologically, over successive biopsies (Fig. 1 and Table 2). The cases
the most striking difference was the milder tubular epi- with diminution in fibrosis also showed substantially less
thelial lesions in the massive deposits group, both at Bx1 glomerular sclerosis, less interstitial inflammation, and
and Bx2. The inflammation also tended to respond better better outcomes and final renal function than those
to therapy at Bx2 and Bx3. whose interstitial fibrosis progressed (Table 2). It is rea-
sonable to conclude that in these patients the balance
Relative lack of overlap between groups with good between synthesis and degradation of ECM now favored
prognostic features degradation, and to speculate that this shifted balance
Four groups were found to have a good prognosis in represents primarily quiescence of TIMP-1 and PAI-1.
this study: the Intfib↓ patients, the Gloscar↓ group, those The substantially lesser degree of interstitial inflamma-
with initial marked hyaline deposits but little inflamma- tion in these patients supports this suggestion. (Obvi-
ously, in any given case, sampling error is a major consid-tion, and those with no history of renal relapse. A legiti-
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Table 3. Variables significantly associated with renal relapse, CRX2, and ESRD at biopsy 2 univariate analysis
Renal relapse CRX2 ESRD
Beta P Beta P Beta P
Composite variables
Biopsy inflammation 0.27 0.003 0.59 0.0000 0.46 0.0003
Total Ig–IF 0.10 0.06 0.09 0.14 0.04 0.47
Individual variables
Glomerular proliferation 0.56 0.03
Glomerular PMNs 1.35 0.007 1.03 0.01
Karyorrhexis/fibrinoid necrosis 1.03 0.003 0.94 0.0007
Cellular crescents 1.77 0.001 2.00 0.00006
Glomerular monocytes 0.66 0.05 0.83 0.009
Fibrous crescents 1.00 0.05 1.28 0.02
Glomerular scars 0.58 0.05 0.58 0.06
Tubular nuclear activation 0.81 0.02
Macrophages–tubular lumens 2.72 0.0003 2.23 0.003
Epithelial cells–tubular lumens 0.96 0.01 0.76 0.06
Interstitial inflammation 0.51 0.006
Glomerular capillary IF 0.20 0.002 0.14 0.02
Vascular IF 0.20 0.03 0.24 0.02
Tubular IF 0.19 0.003 0.16 0.02
IgG–IF 0.18 0.07 0.13 0.07
C3–IF 0.31 0.006 0.43 0.003 0.40 0.002
C1q–IF 0.23 0.002 0.18 0.03
Fibrinogen–IF 0.43 0.02 0.44 0.05
Subendothelial deposits–IF 0.62 0.02 0.56 0.06
Includes all cases with complete light microscopic, immunofluorescence (IF), and follow-up data (50 cases). Only variables significant for at least one outcome
included.
Table 4. Cox proportional hazards modeling of renal relapse,
Table 5. Comparison of cases with marked hyaline deposits andCRX2, and ESRD biopsy 2
minimal inflammation with other cases of diffuse
proliferative lupus nephritisBeta P
Renal relapse Hyaldep1  3 Other diffuse
Composite variables BxInfl1  7 proliferative
Biopsy inflammation 0.3168 0.0033 (14 patients)a (38 patients)a P
Total Ig deposits 0.0148 0.77
SCr–1 13968 13078 NSChronic lesions 0.05693 0.62
SCr–2 10029 9532 NSIndividual variables
SCr–3a 9824 16793 0.040Karyorrhexis/fibrinoid necrosis 0.7671 0.014
C3 0.2304 0.056 Proteinuria-1 4.45.1 5.43.8 NS
CRX2 Proteinuria-2 1.22.0 1.61.9 NS
Composite variables Proteinuria-3a 1.31.2 4.52.9 0.0060
Biopsy inflammation 0.6070 0.000009
ESRD 0.0000 0.3514 0.013Total Ig deposits 0.0327 0.54
CRX2 0.0714 0.4474 0.014Chronic lesions 0.0906 0.36
Rflast 10061 261197 0.0044Individual variables
Cellular crescents 2.3457 0.00011 Chronic Lesions Index 1 2.42.2 3.02.7 NS
Macrophages in tubular lumens 2.0804 0.016 Chronic Lesions Index 2 3.22.4 4.22.7 NS
Epithelial Cells in tubular lumens 1.5379 0.0046 Chronic Lesions Index 2a 3.32.7 5.33.3 NS
C3 0.6014 0.0036
Tubular epithelial-1 3.21.6 5.12.5 0.014ESRD
Tubular epithelial-2 2.91.7 4.22.6 0.089Composite variables
Tubular epithelial-3a 2.31.9 4.72.7 0.026Biopsy inflammation 0.4974 0.0008
Total Ig deposits 0.0368 0.55 IFIndex-1 24.39.2 27.97.2 NSChronic lesions 0.1927 0.11 IFIndex-2 17.713.1 16.28.2 NSIndividual variables IFIndex-3a 16.510.0 21.09.0 NSCellular crescents 3.1766 0.00074
Fibrous crescents 2.1758 0.049 Biopsy inflammation-1 5.01.6 7.33.1 0.012b
Macrophages in tubular lumens 4.9381 0.0054 Biopsy inflammation-2 1.31.7 2.31.9 0.090
Epithelial Cells in tubular lumens 2.1962 0.054 Biopsy inflammation-3a 1.32.1 3.62.7 0.036
C3 0.8388 0.043
Data includes only cases with a complete follow-up.
a At Bx3 there were only 9 biopsies in the Hyaldep  3 group and 18 biopsiesIncludes only cases with complete light microscopic, IF, and follow-up informa-
in the other diffuse proliferative grouption (50 cases). Composite and individual variables tested separately. All Cox
b Partly due to initial group definitionmodels are significant at P  0.03 or less.
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eration. However, these cases were present in sufficiently do not, gives a notion of the substrate on which future
relapses will be superimposed. Continuing inflammationlarge numbers and their clinical behavior was sufficiently
distinctive that sampling error could be ruled out statisti- and mounting chronic lesions also serve to partially ex-
plain why some patients simply slowly degrade their re-cally as an explanation for the overall differences.)
In humans, reversal of glomerular and interstitial fi- nal function without an event sufficiently dramatic to be
labeled relapse.brotic lesions has been demonstrated formally only in
two other studies, both of which were focused on diabetic Similarly, we found that the opposite face of relapse,
failure to remit, was associated with a higher rate ofnephropathy [29, 30]. In one early case report the lesions
in diabetic kidneys transplanted into two non-diabetic pa- CRX2 (64.8 vs. 13.0%, P  0.00034). Our experience is
thus comparable with that of Korbet et al, who foundtients resolved within seven months [29]. In the other study,
lesions of diabetic nephropathy reversed over a period that failure of remission was associated with a high rate
of CRX2 [6].of ten years in eight diabetic patients receiving pancreas
transplantation [30]. However, ours is the first study in
Role of immunoglobulin deposits and inflammatorywhich diminution of fibrous lesions has been systemati-
lesions in relapse and progressioncally demonstrated outside the transplantation setting.
It must be noted, however, that two other groups have One of the striking findings in our study was that
Total Ig was not significantly associated with relapse orfound a possible reduction of chronic lesions over succes-
sive biopsies, but both are without comment [31, 32]. progression, whereas BxInfl was strongly associated with
progression, and C3 deposits were increasingly impor-
Renal relapse and progression of lupus nephritis tant with worsening disease. Other recent studies also
failed to identify any prognostic significance for immuneMoroni et al found that renal relapse is associated
with an extremely high rate of progression to CRX2 and deposits [33, 34]. These observations are subject to im-
portant caveats, since neither our own nor the otherESRD [4], and this was true in our series as well. Of 56
patients who initially responded to therapy, all those who studies cited examined possible differences in IgG sub-
types, antibody affinity, and other variables that deter-progressed to CRX2 (11 patients) suffered subsequent
relapse. However, 11 of 47 patients (23.4%) who did not mine ability to elicit inflammation [17, 35].
However, even with these provisos, it has been demon-progress also suffered relapses. Analysis revealed that
there were two interrelated differences between those strated experimentally in two settings that the link be-
tween Ig deposits and inflammation is not obligate. First,who relapsed and progressed to CRX2 and those who
relapsed but did not progress. First, inflammation and experimentally it is possible to have substantial Ig depos-
its in the absence of significant inflammation and fibrosisimmune deposits in the Relapse-No CRX2 group re-
sponded as fully to therapy at Bx2 as in the No Relapse- [36, 37]. The present study presents a group of patients
who are at least partially the clinical analogs of these ani-No CRX2 group (Fig. 3 A, B), and if the limited data
at Bx4 are to be believed (Fig. 4), responded once again mal models, having marked deposits but only modest in-
flammation, and excellent outcomes, demonstrating thatmore fully to therapy than those who progressed to
CRX2. Second, chronic lesions actually declined be- it is not the absolute amount of deposits but the associ-
ated inflammation that counts in the outcome. More im-tween Bx2 and Bx3 in the Relapse-No CRX2 group
whereas chronic lesions steadily progressed in the CRX2 portantly, it is possible experimentally to produce glo-
merulosclerosis and interstitial nephritis in the totalgroup. Thus, the active lesions at the time of relapse
were superimposed on more severe chronic lesions in absence of immune deposits in lupus-prone mice geneti-
cally incapable of elaborating Ig [38], probably via B cellthe CRX2 group. One may speculate as well that the
lesser reduction in inflammation at Bx2 in the CRX2 activation of T cells [39, 40].
Similarly, we simply have an estimation of the globalgroup led to ongoing damage responsible for the higher
CLI at Bx3, whereas in the No CRX2 groups, inflamma- quantity of inflammation in its various guises. We do not
have any information about the types of infiltrating cells,tion was sufficiently quiescent as to permit regression of
fibrous lesions. as to Th1 versus Th2 lymphocytes, B cells, and macro-
phages, all of which have been shown to be importantThus, we have partially answered one of the questions
posed in the introductory comments as to how the lesions in determining the severity of lupus nephritis [40–43],
nor do we have any way of determining what proportionon biopsy at six months can predict events far in the
future, despite the intervention of renal relapses. The of the inflammation is in direct response to immune
complex deposition, and what proportion is due to otherinitial response of inflammation and Ig deposits appears
to predict how the patient will respond to possible future cell-mediated processes. Tentative evidence that the pro-
portion of inflammation due to cell-mediated mecha-renal relapses. Second, the fact that chronic lesions par-
tially revert in patients who have fully responded to nisms was greater in the CRX2 group is the observation
that at Bx1, although the levels of Ig deposits are virtuallytherapy, whereas they continue to mount in those who
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